




FIG. 1




FIG. 2A




FIG. 2B




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10





FIG. 11



◊ RAS(ON) Inhibitor doublet evaluated across seven models, including five identified as resistant to RMC-6291 monotherapy

(1) RVMD preclinical research: NSCLC = non-small cell lung cancer; Compound A dosed at 25 mg/kg po qd (n=52); RMC-6291 dosed at 100 or 200 mg/kg po qd (n=52); Combination (n=51). For each group, n = total number of animals from the seven models that comprise the dataset. Progression defined as tumor doubling from baseline.

FIG. 12